SCHEMBL4124278

SCHEMBL4124278

Nc1nn2c(-c3ccc(Cl)cc3)c(-c3ccccc3Cl)cnc2c1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 5/20 0.46
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
MAPT P10636 5/20 0.43
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
EGLN1 Q9GZT9 1/20 0.38
AHR P35869 1/20 0.38
USP7 Q93009 2/20 0.37
GAA P10253 1/20 0.37
SCN9A Q15858 1/20 0.36
NTRK1 P04629 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2087359 0.89 MAP4K4 (0.42) MAP4K4MAPTALDH1A1KMT2AMEN1
SCHEMBL4124557 0.87 RAB9A (0.41) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2084105 0.86 PTGS2 (0.38) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2084318 0.85 NPC1 (0.36) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2085649 0.85 NR3C1 (0.39) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2084056 0.85 RAB9A (0.38) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2086776 0.85 ALDH1A1 (0.49) NPC1RAB9AMAPTALDH1A1SMN1; SMN2
SCHEMBL4124245 0.83 NPC1 (0.43) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2085454 0.83 RXFP1 (0.38) MAP4K4NPC1RAB9AMAPTALDH1A1
SCHEMBL2084563 0.82 CNR1 (0.46) NPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD MAP4K4 3216/4885NPC1 3153/4885RAB9A 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.